Review

NF-κB Signaling in Targeting Tumor Cells by Oncolytic Viruses—Therapeutic Perspectives

Justyna Struzik * and Lidia Szulc-Dąbrowska

Division of Immunology, Department of Preclinical Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, Ciszewskiego 8, 02-786 Warsaw, Poland; lidia_szulc@sggw.pl
* Correspondence: justyna_struzik@sggw.pl; Tel.: +48-22-59-360-61

Received: 4 October 2018; Accepted: 6 November 2018; Published: 8 November 2018

Abstract: In recent years, oncolytic virotherapy became a promising therapeutic approach, leading to the introduction of a novel generation of anticancer drugs. However, despite evoking an antitumor response, introducing an oncolytic virus (OV) to the patient is still inefficient to overcome both tumor protective mechanisms and the limitation of viral replication by the host. In cancer treatment, nuclear factor (NF)-κB has been extensively studied among important therapeutic targets. The pleiotropic nature of NF-κB transcription factor includes its involvement in immunity and tumorigenesis. Therefore, in many types of cancer, aberrant activation of NF-κB can be observed. At the same time, the activity of NF-κB can be modified by OVs, which trigger an immune response and modulate NF-κB signaling. Due to the limitation of a monotherapy exploiting OVs only, the antitumor effect can be enhanced by combining OV with NF-κB-modulating drugs. This review describes the influence of OVs on NF-κB activation in tumor cells showing NF-κB signaling as an important aspect, which should be taken into consideration when targeting tumor cells by OVs.

Keywords: immunotherapy; NF-κB signaling; oncolytic viruses

1. Introduction

Since its discovery in 1986, nuclear factor (NF)-κB has been widely studied and is well known as a pleiotropic transcription factor, which orchestrates inflammation, innate and adaptive immune responses, cell growth, and apoptosis. Therefore, deregulation of NF-κB activation pathways may result in autoimmune diseases and tumorigenesis. Importantly, NF-κB and its target genes have been shown to play a role in malignant transformation, proliferation, and survival of cancer cells, as well as angiogenesis and invasion/metastasis. Moreover, aberrant NF-κB signaling is associated with aggressiveness, recurrence, and therapeutic resistance of tumors. Therefore, NF-κB is considered a good candidate for the therapeutic target, becoming an important focus in cancer research [1–4].

Chemotherapy, which is widely used for cancer treatment, is mainly aimed at apoptosis, necrosis, autophagy, and mitotic catastrophe. Importantly, cellular senescence, resulting from chemotherapy treatment, involves NF-κB activation. This suggests that blockage of NF-κB would prevent this outcome. Unfortunately, due to the pleiotropic nature of NF-κB, the use of NF-κB inhibitors in cancer therapy may not always be beneficial. Apoptotic defects of cancer cells are responsible for chemoresistance. Therefore, these factors should be considered when targeting NF-κB in cancer treatment [1].
2. Overview of NF-κB Signaling

NF-κB is a family of transcription factors, which is composed of the following proteins: RelA/p65, RelB, c-Rel, NF-κB1/p105, and NF-κB2/p100. In resting cells, NF-κB localizes mainly to the cell cytoplasm as RelA/p50 heterodimers coupled with an inhibitor of κB (IκB). Other heterodimers comprise RelB and p100, a p52 precursor protein, which acts in a similar manner as IκB, maintaining the state of the cytoplasmic arrest of NF-κB [4,5]. p105 and p100 phosphorylation result in their 26S proteasome-induced processing via the activity of Skp-Cullin-F-box (SCF) ubiquitin E3 ligase. These events generate p50 and p52 active subunits allowing nuclear translocation of heterodimers comprising RelA/p50 or RelB/p52 and the transcription of target genes [5].

Canonical (classical) NF-κB signaling pathway, which results in nuclear translocation of RelA/p50 and c-Rel/p50 dimers, is triggered by certain receptors activated by proinflammatory cytokines, such as tumor necrosis factor (TNF)-α. Other stimuli of canonical NF-κB signaling, such as lipopolysaccharide (LPS), belong to pathogen-associated molecular patterns (PAMPs), which activate Toll-like receptors (TLRs). Canonical NF-κB activation pathway is also triggered by activators of receptors of B- and T cells (BCR and TCR), stimulatory molecules of receptor activator of NF-κB (RANK), as well as a cluster of differentiation 30 (CD30) and CD40 ligands (Figure 1) [4]. Cellular receptors bind cellular inhibitor of apoptosis protein-1 (c-IAP1) and c-IAP2, which cooperate with TNF receptor-associated factor 2 (TRAF2) adapter protein. Following canonical NF-κB activation, IκB kinase complex (IKK), comprising IKKα, IKKβ, and IKKγ/NF-κB essential modulator (NEMO) components, is activated by transforming growth factor-β-activated kinase 1 (TAK1). IKK activation triggers phosphorylation, ubiquitination, and proteasomal degradation of IκB. These events enable the release and nuclear translocation of predominantly p65/p50 heterodimers. Canonical NF-κB activation, which does not depend on protein synthesis, is described as rapid and transient. Canonical NF-κB signaling controls cell survival, innate immunity, regulation of the type I interferon (IFN) antiviral response, and inflammation [6,7].

Non-canonical (alternative) NF-κB activation pathway is typically induced by TNF receptor (TNFR) superfamily, including lymphotoxin-β receptor (LTβR), B cell-activating factor receptor (BAFF-R), CD40, and TNF-like weak inducer of apoptosis (TWEAK) (Figure 1) [7,8]. In unstimulated cells, NF-κB-inducing kinase (NIK) undergoes persistent degradation by TRAF3. Upon receptor stimulation, c-IAP, c-IAP2, and TRAF2 degrade TRAF3. As a result, NIK is stabilized, inducing IKKα phosphorylation. Afterward, RelB-associated NF-κB2 p100 undergoes NIK/IκKα-induced phosphorylation and proteasomal processing [6–10]. Finally, in order to control the transcription of genes responsible for adaptive immunity, encompassing immune organ and B-cell development, dendritic cell (DC) activation, and bone metabolism, RelB/p52 complexes translocate to the nucleus. Non-canonical NF-κB signaling is slow, persistent, and relies on protein synthesis [7,8]. Alterations in the non-canonical NF-κB activation are linked to inflammation, autoimmune diseases, lymphoid malignancies, and osteoporosis [7]. Despite different functions, canonical and non-canonical NF-κB signaling are linked due to cross-talk mechanisms [11]. The link between the two signaling pathways may also exist via the activity of NIK kinase, which may stimulate both non-canonical and canonical NF-κB signaling pathways [12].
Figure 1. Canonical and non-canonical nuclear factor (NF)-κB signaling. Activation and inhibition of NF-κB signaling components are indicated by pointing and blunt arrows, respectively. BAFF-R, B cell-activating factor receptor; BCR, B-cell receptor; CD30, cluster of differentiation 30; CD40, cluster of differentiation 40; c-IAP1, cellular inhibitor of apoptosis protein-1; c-IAP2, cellular inhibitor of apoptosis protein-2; IKKα, inhibitor of κB kinase α; IKKβ, inhibitor of κB kinase β; IKKγ, inhibitor of κB kinase γ; IκB, inhibitor of κB; LTβR, lymphotoxin-β receptor; NIK, nuclear factor-κB-inducing kinase; P, phosphate group; RANK, receptor activator of nuclear factor-κB; TAK1, transforming growth factor-β-activated kinase 1; TCR, T-cell receptor; TLRs, Toll-like receptors; TNF-α, tumor necrosis factor-α; TRAF2, tumor necrosis factor receptor-associated factor 2; TRAF3, tumor necrosis factor receptor-associated factor 3; TWEAK, tumor necrosis factor-like weak inducer of apoptosis; Ub, ubiquitin moieties.

3. NF-κB in Oncogenesis

NF-κB's role in oncogenesis was first identified when v-rel oncogene, a c-Rel homolog, expressed by reticuloendotheliosis virus strain T, was identified as the key etiological agent of fatal lymphomas in chicken models [4]. Constitutive NF-κB activation is linked to cancer development and can be observed in lymphoid malignancies and tumors of epithelial origin [4,13]. NF-κB's role in cancer is multidirectional because genes encoding both pro-proliferative and anti-apoptotic proteins are under NF-κB's control. Furthermore, NF-κB signaling is linked to other pathways, including activator protein...
1 (AP1), signal transducer and activator of transcription 3 (STAT3), IFN-regulatory factor, Notch, NF-E2-related factor 2 (NRF2), p53, and WNT–β-catenin signaling [14]. If regulatory T (Treg) cells or myeloid-derived suppressor cells (MDSCs) are present in the tumor microenvironment, NF-κB acts as an inhibitor of antitumor responses. Adversely, the role of NF-κB in antitumor immunity leans on inflammatory cells, including perforin-secreting natural killer (NK) cells and tumor-phagocytic macrophages [4]. Nonetheless, chronic inflammation and fibrosis linked to NF-κB stimulation create a tumorigenic microenvironment [13]. In order to upregulate expression of genes encoding cyclooxygenase (COX)-2, nitric oxidase synthase, and proinflammatory cytokines, such as TNF-α, interleukin (IL)-6, -8, and chemokine (C-C motif) ligand (CCL)-2 in immune cells, IL-1, TNF, PAMPs, and damage-associated molecular patterns (DAMPs) activate NF-κB. These molecules, in turn, stimulate NF-κB and STAT3 in tumor cells and surrounding tissues to promote cancer survival, invasion and metastasis [14]. Importantly, RelA-dependent chemokine (C-X3-C motif) ligand 1 (CX3CL1), which recruits cytotoxic T lymphocytes (CTLs) and NK cells and exerts an antitumor effect, supports TNF-related apoptosis-inducing ligand (TRAIL) resistance and the survival of pancreatic ductal adenocarcinoma (PDAC) cells [15]. Similarly, CCL20, produced by PDAC cells, attracts peripheral blood mononuclear cells (PBMCs) to increase TRAIL resistance of pancreatic cancer cells [16].

NF-κB controls epithelial-mesenchymal transition and the expression of cell adhesion molecules (CAMs), such as E-selectin, intracellular CAM (ICAM)-1, vascular CAM (VCAM)-1, and integrins [14,17]. However, inhibition of NF-κB may not be beneficial for anticancer therapy since angiogenesis is antagonized by NF-κB. In addition, tumor invasion of adjacent tissues is associated with NF-κB-dependent matrix metalloproteinases (MMPs) [3,14]. NF-κB is also involved in metabolism switch from oxidative phosphorylation to glycolysis [14].

Suppression of intrinsic and extrinsic apoptotic pathways by NF-κB may arise from upregulation of IAP family members upon TNFR stimulation. IAPs not only inhibit caspase activation, but may also stimulate NF-κB, thus enhancing the anti-apoptotic effect. Indeed, in cancer cells, IAPs’ overexpression can be observed [13]. Cell survival and resistance to anticancer therapeutics can also be achieved via growth factors and their receptors, such as epidermal growth factor receptor, and other factors, for example, rat sarcoma (Ras) oncoprotein. TRAF family member-associated NF-κB activator-binding kinase 1 (TBK1), activated downstream of Ras and growth factor receptors, stimulate NF-κB via c-Rel. NF-κB can also be activated by breakpoint cluster region (Bcr)-Abelson leukemia oncogene (Abl) fusion protein, associated with chronic myeloid leukemia and acute lymphoblastic leukemia, via activation of IKKs. Importantly, in promoting both NF-κB-dependent and -independent cell survival, IKKs are regarded as key players [2].

Elevated IKK activation can be observed in leukemia, lymphoma, multiple myeloma (MM), as well as in breast cancer, colorectal cancer, and prostate cancer. IKK expression is also correlated with cell survival in clear cell renal cell carcinoma (CCRCC) [18,19]. Importantly, silencing IKK subunits using small interfering RNA (siRNA) or treatment with IKK inhibitor helps sensitize cancer cells to chemotherapy and trigger cell death [18].

The role of NF-κB in replicative immortality involves upregulation of the telomerase catalytic subunit (TERT)-encoding gene, whereas the expression of NF-κB-dependent genes is regulated by TERT [17]. Also, genetic instability can be acquired via the DNA damage induced by oxidative stress, which activates NF-κB [2,17]. NF-κB’s direct role in cancer is based on the mutations of NF-κB regulatory proteins. Mostly, gain-of-function mutations of upstream NF-κB activators are responsible for NF-κB-driven cancers [2,4,17]. In addition, genetic and chromosomal alterations of NF-KB1, NF-KB2, and REL are typical for a variety of types of blood cancers [2,17].

Oncogenic transformation is also linked to certain viral factors, which act antiapoptotically via persistent activation of NF-κB signaling in the host cells. The canonical and non-canonical NF-κB signaling pathways are induced via TRAFs by Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1), leading to Hodgkin’s lymphoma. IKKs can be stimulated by Tax
oncogene of human T-cell leukemia virus type 1 (HTLV-1), a causative agent of adult T-cell leukemia. Kaposi’s sarcoma-associated herpesvirus (KSHV) activates IKKγ via anti-apoptotic protein viral FLICE inhibitory protein (vFLIP) [2,4,7,20].

Since apoptotic stimuli, such as proinflammatory TNF, chemotherapeutic daunorubicin, as well as ionizing radiation may be responsible for the anti-apoptotic role of NF-κB, it is important to inhibit NF-κB during cancer treatment to overcome tumor resistance. This approach of selective NF-κB inhibition can be used in gastric cancer chemotherapy, as well as in melanoma doxorubicin treatment, which is performed together with IKK inhibition [17]. Upon targeted NF-κB inhibition, TRAIL-induced cancer cytotoxicity is observed [17,21]. It is also worth noticing that TNF superfamily members, for example, TWEAK, activate NF-κB-dependent TNF expression resulting in cell death. Thus, NF-κB may act proapoptotically [21].

4. OVs

OVs, belonging to new generation of cancer immunotherapeutics, are natural or genetically modified pathogens, which infect and replicate in cancer cells but not in non-transformed cells, and trigger both antiviral and antitumor responses [22]. Upon administration of OV, the virus infects tumor cells resulting in their lysis. As a consequence of tumor-derived antigens’ (TDAs) release, antigen-presenting cells (APCs) uptake and process TDAs to activate and prime T cells. Thus, the effector cells localize to, infiltrate, and eventually kill the tumor cells. Afterward, released TDAs are processed by APCs [23]. Nevertheless, using OVs as monotherapy may not be efficient due to the limited replication of the virus in the host, tumor resistance to the response generated, and immunosuppression within the tumor microenvironment [22].

In oncolytic virotherapy, one of the main concerns is the presence of neutralizing antibodies, which can already be found in patients vaccinated or previously treated with OVs [24,25]. This effect can be observed in MM patients treated with systemically administered measles virus armed with human thyroidal sodium iodide symporter (MV-NIS) [24]. Upon intravenous delivery of OV, both antibodies and complement promote Fc receptor-linked clearance of the virus by Kupffer cells and splenic macrophages [25]. However, such administration is not always beneficial. For instance, oncolytic herpes simplex virus type 1 (HSV)-1, which spreads from cell to cell, and is used for melanoma treatment, is more effective when administered intralesionally [24]. Nevertheless, intratumoral injection of an OV may not be efficient in the treatment of disseminated tumors, whereas systemic administration of a drug in trans with OV delivery may result in toxicity and increases the costs. Adversely, delivery of therapeutic gene product or a single therapeutic in cis may not be efficient when sustained expression is required [26]. Therefore, many therapeutic approaches based on OVs are under clinical trials. Nevertheless, the United States Food and Drug Administration (FDA) approved Talimogene laherparepvec (T-VEC), a modified HSV, in metastatic melanoma treatment [22,23,27,28]. In clinical trials, metastatic melanoma patients are given intralesion injections of T-VEC combined with intravenous pembrolizumab (anti-programmed death [PD]-1). This treatment represents a strategy of switching immunologically “cold” tumor, which is characterized by the absence or low tumor-infiltrating lymphoid cells (TILs), into “hot.” The latter is defined by the presence of TILs in their microenvironment due to induction of proinflammatory response and activation of DCs and NK cells [22,29].

TILs are represented by subpopulations of CD3+CD4+ helper and CD3+CD8+ cytotoxic T cells [30], Tregs, NK cells, B cells, DCs, macrophages, and MDSCs [31]. TILs comprise epithelial, stromal, and peritumoral lymphocytes located in cancer cell nests, central stroma, and invasive margins, respectively. Although TILs may display higher reactivity toward tumor cells compared with non-infiltrating lymphocytes, they may promote tumor growth. Importantly, the presence and immunophenotype of TILs serve as a prognostic factor in melanoma, breast cancer, ovarian cancer, lung cancer, and renal cell carcinoma (RCC). For instance, in advanced melanoma, TILs Treg CD4+CD25+ are linked to progression of the disease [30].
TILs obtained from resected tumors are used as effector cells in adoptive T-cell therapy (ATC), which can be combined with chemotherapy and immunotherapeutic drugs to maintain TILs proliferation and proper function to target tumor-associated antigens (TAAs). After ex vivo propagation and activation, TILs and IL-2, a T-cell growth factor, are administered autologously to lymphodepleted patients [30,32,33]. To facilitate virus entry to the tumor, TILs may be genetically modified with C-X-C chemokine receptor type 2 (CXCR2) [34]. The improvement of antitumor activity in vitro can also be obtained by blockade of transforming growth factor (TGF)-β signaling [35]. With durable responses being observed, TILs have been implemented in late-stage metastatic melanoma in clinical studies [33]. Clinical studies are currently carried on TILs combined with anti-CTLA-associated protein (CTLA)-4 monoclonal antibodies (mAbs) (ipilimumab) (NCT01701674), peginterferon α-2b upregulating human leukocyte antigen (HLA) expression on tumor cells (NCT02379195), and nivolumab (anti-PD-1 mAbs) with or without IFN-α (NCT03638375) for metastatic melanoma treatment. Other clinical trials implementing TILs are focused on the treatment of nasopharyngeal carcinoma (NCT02421640), malignant pleural mesothelioma (NCT02414945), cervical carcinoma (NCT03108495), and squamous cell carcinoma of the head and neck (NCT03083873). Also, TILs along with pembrolizumab and other drugs are tested against aggressive tract, urothelial, breast, ovarian/endometrial tumors (NCT01174121). For non-small cell lung cancer (NSCLC), TILs with durvalumab (anti-PD-ligand 1 (PD-L1) mAbs) (NCT03419559), nivolumab, and other drugs are under clinical trials (NCT03215810). TILs are also tested in treatment of uveal neoplasms (NCT03467516), platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer (NCT01883297).

The expression of PD-1 on T cells is important in ATC. PD-1 binds tumor-associated PD-L1 and PD-L2, which interfere with T-cell activation, major histocompatibility complex (MHC), and TCR interaction, and induces T-cell apoptosis. Other immune checkpoint protein, CTLA-4 suppresses T-cell activation. Therefore, to induce the immune response, CTLA-4 or PD-1 interactions with ligands can be disrupted by mAbs in cancer immunotherapy [30].

In metastatic melanoma, injection of T-VEC results in local inflammation, the presence of type I IFNs, and granulocyte-macrophage-colony-stimulating factor (GM-CSF)-attracted DCs, leading to subsequent cell killing. Anti-PD-1 blocks the interaction between PD-1 on activated T cells and PDL-1 on tumor cells. Thus, T cells are reactivated to destroy the tumor [29]. Another target in antitumor therapy, CTLA-4, which can be expressed on tumor cells, infiltrating Tregs as well as on exhausted conventional T cells, is regarded as an immunosuppressive factor, but its role as a prognostic factor is unclear [36]. In advanced melanoma stage IIIc and IV treated with intratumoral injections of coxsackievirus A21 (CVA21), which infects ICAM-1 expressing cancer cells, antitumor response has been shown in clinical trials. Importantly, in preclinical studies on a mouse model, the use of anti-PD-1 or anti-CTLA-4 mAbs together with CVA improved anti-tumor response [37].

Certain viral vectors described below and derived from oncolytic DNA (adenovirus (AV), HSV-1, parvovirus (PV)) and RNA viruses (reovirus (RV) and vesicular stomatitis virus (VSV)) presented in this review are currently under clinical trials (Table 1).

In tumor cells, the cellular response toward oncolytic DNA (Figure 2) and RNA viruses (Figure 3) is influenced by NF-κB. Since NF-κB is a key player in tumorigenesis, NF-κB activation level may indicate the effectiveness of oncolytic virotherapy.
Table 1. Oncolytic DNA and RNA viruses in clinical trials. A selected list includes viruses described in the text.

| OV          | Treatment                                      | Condition                          | Status       | Phase | References          |
|-------------|------------------------------------------------|------------------------------------|--------------|-------|---------------------|
| AV          | Ad5-γCD/mutTKSR39rep-ADP (Theragen®) 5-FC vGCV SBRT | Non-small cell lung cancer stage I | Recruiting   | I     | NCT03029871         |
|             | Ad5-γCD/mutTKSR39rep-S9L12                       | Prostate cancer                    | Recruiting   | I     | NCT0255597         |
|             | Ad5-γCD/mutTKSR39rep-S9L12 5-FC                  | Metastatic pancreatic cancer       | Recruiting   | I     | NCT03281382        |
|             | ADV/HSV-tk Valacyclovir SBRT                      | Metastatic non-small cell lung cancer Metastatic triple-negative breast cancer | Recruiting   | II    | NCT03004183    |
|             | CG0070                                          | Bladder cancer                     | Active, not recruiting | II    | NCT02365818        |
|             | DNX-2401 (Delta-24-RGD-4C) Neoadjuvant therapy   | Brainstem glioma                   | Recruiting   | I     | NCT03178032        |
|             | DNX-2401 (Delta-24-RGD-4C) Pembrolizumab         | Glioblastoma Glissocarcinoma       | Recruiting   | II    | NCT02798406        |
|             | DNX-2440                                         | Recurrent glioblastoma             | Recruiting   | I     | NCT03714334        |
|             | LOAd703                                          | Biliary carcinoma                  | Recruiting   | I/II  | NCT03225989        |
|             | LOAd703 Gemcitidine Nab-paclitaxel                | Pancreatic cancer                  | Recruiting   | I/II  | NCT02705196        |
|             | NSC-CRAAd-8-pk7                                  | Malignant glioma                   | Recruiting   | I     | NCT03072134        |
|             | OBP-301 (Telomelysin)                            | Melanoma stage III-IV              | Recruiting   | II    | NCT03190824        |
|             | ONCOS-102 Cyclophosphamide DCVac/PCa             | Castration-resistant prostate cancer | Recruiting   | I/II  | NCT03514836        |
|             | ONCOS-102 Cyclophosphamide Pembrolizumab         | Advanced or unresectable melanoma progressing after PD-1 blockade | Recruiting   | I     | NCT0303676    |
|             | ONCOS-102 Cyclophosphamide Pembrolizumab         | Malignant pleural mesothelioma     | Recruiting   | I/II  | NCT02879669        |
|             | VCN-01 Gemcitbine Abraxane®                      | Locally advanced solid tumors      | Recruiting   | I     | NCT02045602        |
|             | CI34                                              | Recurrent malignant glioma         | Not yet recruiting | I     | NCT03657976        |
|             | G207                                              | Supratentorial neoplasms, malignant | Recruiting   | I     | NCT02457945        |
|             | M032 (NSC 733972)                                | Recurrent malignant glioma         | Recruiting   | I     | NCT02062927        |
|             | rQNestin34.5v2 (rQNestin) Cyclophosphamide       | Recurrent malignant glioma         | Recruiting   | I     | NCT03152318        |
|             | TBI-1401(HF10) (Canerpaturev) Gemcitbine Nab-paclitaxel TS-1 | Pancreatic cancer stage III-IV | Recruiting   | I     | NCT03252808        |
|             | TBI-1401(HF10) (Canerpaturev) Ipiilimumab         | Melanoma stage III-IV              | Active, not recruiting | II    | NCT03153085        |
| HSV-1       | T-VEC                                            | Basal cell carcinoma               | Recruiting   | I     | NCT03458117        |
|             |                                                  | Cutaneous lymphoma                 | Recruiting   | I     | NCT02658812        |
|             |                                                  | Merkel cell carcinoma              |               |      |                     |
|             |                                                  | Non-melanoma skin cancer           |               |      |                     |
|             |                                                  | Squamous cell carcinoma            |               |      |                     |
|             |                                                  | Recurrent breast cancer that cannot be removed by surgery | Active, not recruiting | II    | NCT02658812        |
Table 1. Cont.

| OV     | Treatment | Condition                                      | Status          | Phase | References       |
|--------|-----------|------------------------------------------------|-----------------|-------|------------------|
| T-VEC  | Anastrozole Exemestane Fulvestrant Letrozole Paclitaxel Tamoxifen | Metastatic, unresectable, or recurrent HER2-negative breast cancer | Not yet recruiting | I     | NCT03554044     |
| T-VEC  | Capcitabine Fluorouracil Oxaliplatin | Locally advanced or metastatic rectal cancer | Recruiting     | I     | NCT03300544     |
| T-VEC  | Nivolumab | Refractory T cell and NK cell lymphomas Cutaneous squamous cell carcinoma Merkel cell carcinoma Other rare skin tumors | Recruiting     | II    | NCT02978625     |
| T-VEC  | Paclitaxel | Breast cancer Ductal carcinoma Invasive breast carcinoma Invasive ductal breast carcinoma | Recruiting     | I/II  | NCT02779855     |
| T-VEC  | Pembrolizumab | Melanoma stage III-IV | Recruiting     | II    | NCT02965716     |
| PV     | H-1PV (ParvOryx™) | Metastatic inoperable pancreatic cancer | Recruiting     | I/II  | NCT02653313     |
| RV     | REOLYSIN® Irritoeucn Leucovorin 5-FU Bevacizumab | KRAS mutant metastatic colorectal cancer | Active, not recruiting | I     | NCT01274624     |
| RV     | Wild-type Reovirus Bortezomib Dexamethasone | Relapsed or refractory multiple myeloma | Active, not recruiting | I     | NCT02514382     |
| RV     | Wild-type Reovirus Carfilzomib Dexamethasone Nivolumab Pomalidomide | Recurrent plasma cell myeloma | Not yet recruiting | I     | NCT03605719     |
| RV     | Wild-type Reovirus Paclitaxel | Recurrent fallopian tube carcinoma Recurrent ovarian carcinoma Recurrent primary peritoneal carcinoma | Active, not recruiting | II    | NCT01199263     |
| VSV    | VSV-hIFNβ-NIS Technetium Tc-99m Sodium Perchelmate | Stage IV or recurrent endometrial cancer | Recruiting     | I     | NCT03120624     |
| VSV    | VSV-hIFNβ-NIS VSV-hIFNβ-NIS and Avelumab | Malignant solid tumor | Recruiting     | I/II  | NCT02923466     |
| VSV    | VSV-hIFNβ-NIS Pembrolizumab | Refractory non-small cell lung cancer or Hepatocellular carcinoma | Not yet recruiting | I     | NCT03647163     |

Abbreviations: 5-FC, 5-fluorocytosine; 5-FU, 5-fluorouracil; AV, adenovirus; HER2, human epidermal growth factor receptor 2; hIFNβ, human interferon β; hIL12, human interleukin-12; HSV-1, herpes simplex virus type 1; NIS, sodium iodide symporter; NK, natural killer; OV, oncolytic virus; PD-1 programmed cell death protein 1; PV, parvovirus; RGD, arginine-glycine-aspartic acid; RV, reovirus; SBRT, stereotactic body radiation therapy; tk, thymidine kinase; T-VEC, Talimogene laherparepvec; vGCV, valganciclovir; VSV, vesicular stomatitis virus; yCD, yeast cytosine deaminase.
Figure 2. The impact of oncolytic DNA viruses on nuclear factor (NF)-κB signaling. Activation of NF-κB signaling components is indicated by pointing black arrows. Inhibition of NF-κB is indicated by red blunt arrows. The outcomes of NF-κB modulation are shown in the brackets. Induction is indicated by green triangles, whereas inhibition—by inverted red triangles. 5-FC, 5-fluorocytosine; AV, adenovirus; CCL2, chemokine (C-C motif) ligand 2 gene; CpG, cytosine:guanine islands; CXCL8, C-X-C motif chemokine ligand 8 gene; HSV-1, herpes simplex virus type 1; IRAK4, interleukin-1 receptor–associated kinase 4; MyD88, myeloid differentiation primary response protein 88; PV, parvovirus; TLR9, Toll-like receptor 9; TRAF6, tumor necrosis factor receptor-associated factor 6; TSA, trichostatin A; UPAR, urokinase-type plasminogen activator receptor promoter.
Figure 3. Modulation of nuclear factor (NF)-κB signaling by oncolytic RNA viruses. Pointing black arrows indicate activation of NF-κB signaling components, whereas red blunt arrows indicate NF-κB inhibition. The effects of therapeutic agents on NF-κB are shown in the brackets. Green triangles represent induction, whereas inverted red triangles indicate inhibition. Ac, acetyl group; ActD, actinomycin-D; CDKN1A, cyclin-dependent kinase inhibitor 1 gene; c-Fos, cellular oncogene Fos; EMCV, encephalomyocarditis virus; Epac1, exchange protein directly activated by cyclic adenosine monophosphate isoform 1; Etp, etoposide; IFN-β, interferon-β; IKKα, inhibitor of κB kinase α; IKKβ, inhibitor of κB kinase β; IKKγ, inhibitor of κB kinase γ; IκB, inhibitor of κB; NDV, Newcastle disease virus; P, phosphate group; p38-MAPK, p38 mitogen-activated protein kinase; RSV, respiratory syncytial virus; RV, reovirus; Ub, ubiquitin moieties; VSV, vesicular stomatitis virus.

5. OVs and NF-κB

5.1. DNA Viruses

AVs, belonging to Adenoviridae family, are species-specific double-stranded (ds) DNA viruses, which infect humans and other vertebrates [38]. When used as OVs, AVs may induce unwanted dominant antiviral immune response [25,38,39]. Importantly, the stroma of target tumor blocks the diffusion of the virus, and neutralizing antibody production can be observed even after the intratumoral injection of the virus. Therefore, AV-based oncolytic virotherapies need improvement [25,38].
Nevertheless, the China State Food and Drug Administration approved oncolytic AV, H101 (Oncorine) (Shanghai Sunway Biotech), lacking E1B-55K and E3B proteins, for head and neck cancer therapy [40]. E1B-55K inhibits p53-induced apoptosis, thus playing a protective role against E1A interactions with p53 [41], and influences transport and stabilization of mRNA in the cytoplasm [42]. In addition, genes encoding 6.7K, gp19K, 11.6K E3 proteins, which trigger apoptosis, and therefore may limit viral replication, have been deleted [40].

Another AV, DNX-2401 (DNAtrix), with partial E1A gene deletion in retinoblastoma (Rb)-binding domain and integrin receptor arginine-glycine-aspartic acid (RGD)-4C insertion, which may act against glioma, was designed by FDA as an orphan drug. ONCOS-102 (Oncos therapeutics) with Δ24 deletion within Rb-binding E1A gene, insertion of GM-CSF-encoding gene and replacement of serotype 3 AV knob protein was also granted by FDA as an orphan drug against ovarian cancer, glioma, and malignant mesothelioma [42–44]. ONCOS-102 was tested in preclinical peritoneal mesothelioma model [45], and its efficiency in phase I clinical trials in the treatment of ovarian cancer has been demonstrated [46]. ONCOS-102 expressing GM-CSF is currently under phase I of clinical trials on malignant solid tumors treatment and is likely to prolong the survival of patients with ovarian carcinoma and malignant pleural mesothelioma [47].

The importance of E1A Rb-binding domain in NF-κB regulation has been demonstrated on AV vector AxdAdB-3. AxdAdB-3 is characterized by mutated Rb-binding domain of E1A and lack of E1B-55K and is derived from E1B-55K-deficient AxE1AdB [48]. AxdAdB-3 profoundly reduced NF-κB activity and, therefore, increased NF-κB-mediated apoptosis in comparison with AxE1AdB parent vector in human esophageal carcinoma EC-GI-10 cell line [49].

Oncolytic AV type 5, dl922-947 mutant with deletions in E1A-conserved region 2 (CR2) and subsequent Rb-binding deficiency [50], is a candidate for anaplastic thyroid carcinoma treatment. In 8505-c and BHT101-5 human thyroid carcinoma anaplastic cell lines and TPC1 papillary cells, dl922-947 decreased C-X-C motif chemokine ligand 8 (CXCL8) promoter binding by p65. In addition, dl922-947 reduced CCL2 promoter binding by NF-κB in 8505-c and TPC1 cells by displacing p65 from the promoters. In vitro experiments have shown that the reduction of CXCL8 and CCL2 expression is linked to impaired tumor-induced angiogenesis and reduced chemotaxis. In vivo experiment on anaplastic thyroid carcinoma xenograft mouse model revealed that dl922-947 reduces CXCL8 expression and angiogenesis [51].

Conditionally replicating AV, AduPARE1A, harboring urokinase-type plasminogen activator receptor (UPAR) promoter, which controls E1A region, may act against pancreatic cancer [52]. In human primary pancreatic adenocarcinoma BxPC-3 and pancreas ductal adenocarcinoma PANC-1 cell lines, the synergistic antitumor effect of gemcitabine and AduPARE1A on NF-κB was demonstrated. The UPAR promoter is activated by NF-κB, which, in turn, is stimulated by gemcitabine. Therefore, NF-κB induces UPAR-controlled transgenes, and increase in E1A expression is observed. Competition between the adenoviral promoter and cellular promoters of NF-κB-regulated anti-apoptotic genes may lead to cell sensitization to gemcitabine-induced apoptosis [53].

Another important AV factor, E1B 19K, is a counterpart of mammalian B-cell lymphoma (Bcl)-2, which counteracts E1A-induced apoptosis and interferes with Bad and Bax proapoptotic proteins [54]. It has been shown that E1-deleted replication-defective AV harboring nitroreductase (NR)-encoding gene (RAd-NR) activates IkBα phosphorylation and NF-κB p65/p50 heterodimers in SKOV3 human ovarian carcinoma cell line. In addition, inhibition of NF-κB resulted in restored chemosensitivity of SKOV3 cells because of increased apoptosis. Also, RAd-NR induced NF-κB-dependent mRNA levels of c-IAP1 and c-IAP2, as well as proinflammatory IL-6 secretion. Moreover, conditionally replicating oncolytic E1B-attenuated dl1529 or CR-NR induced NF-κB activation and increased apoptotic threshold in HeLa cells. Importantly, inhibition of NF-κB in SKOV3 cells resulted in enhanced cytotoxic effect and increased apoptosis upon RAd-NR/CB1954 virus-directed enzyme prodrug therapy with the delivery of CB1954 prodrug-activating NR [55].
The E1A 243R and p53-binding E1B 55K AV proteins are known as inhibitors of inflammation upon virus infection, whereas E1B 19K counteracts inflammation in the presence of the two E1A 243R and E1B 55K [56]. Moreover, it has been demonstrated that cytotoxic effect (CPE) resulting from wild-type (wt) AV infection is nonapoptotic. However, human lung adenocarcinoma A549 cells that underwent apoptosis upon infection with Ad5 mutant with E1B 19K-encoding gene deletion (H5dl337) were unable to inhibit NF-κB activation and proinflammatory cytokine responses in macrophages [57].

In order to enhance the antitumor effect, NF-κB activation can be induced via TLR9 by oncolytic Ad5D24-CpG, containing cytosine:guanine (CpG) islands within the genome. Importantly, stimulation of TLR9 induces DCs to type I IFN-mediated activation and proinflammatory IL-12 secretion. These events, in turn, promote NK cell cytotoxicity and IFN-γ secretion to induce antitumor responses. Such observations have been made in A549 lung cancer xenografts model. Also, a syngeneic model of melanoma showed an enhanced tumor response, including a profound drop in both total number and activation of MDSCs [58]. The efficacy of Ad5D24-CpG was also tested in mouse model of melanoma over-expressing chicken ovalbumin (OVA) [59]. Ad5D24-CpG delivering antiproliferative L-carnosine reduced lung and colon tumor growth in mouse xenograft model [60]. Also, in mouse xenograft model of human lung cancer, tumor growth was reduced by using Ad5D24-CpG in combination with paclitaxel [61].

5.1.2. HSV

HSV-1, belonging to family Herpesviridae of neurotropic dsDNA viruses, is a causative agent of a self-limiting disease. Due to its cytopathic replication cycle and easily modified large genome, HSV-1 is beneficial as an oncolytic agent [62,63]. Moreover, HSV-1 infects different cell types, and the presence of a separate attachment and fusion glycoproteins within its envelope is beneficial for modification to improve tumor targeting [63].

The US FDA and European Medicines Agency approved T-VEC (IMLYGIC, Amgen) of GM-CSF-expressing HSV-1 with deletion of γ134.5 gene encoding infected cell protein (ICP)34.5 neurovirulence factor and ICP47-encoding a47 gene deletion in inoperable stage IIIb to IV melanoma. Also, FDA granted G207 with γ134.5 and large subunit of ribonucleotide reductase (UL39) gene deletions (MediGene AG, Martinsried, Germany) as an orphan drug in glioma treatment [44,64].

NF-κB activation might be critical for HSV-1 replication as shown in HT29, SW480 human colon carcinoma and Capan2 human pancreatic cancer cells. Nevertheless, NF-κB-inducing chemotherapy agents, such as TNF-α, 5-fluorouracil (5-FU), and irinotecan (CPT-11), inhibited viral replication in the colon and pancreatic cancer cells infected with HSV-1 KOS strain (HSV-1 KOS). Importantly, 5-FU, CPT-11, but not methotrexate (MTX), activate NF-κB in HT29 cells. MTX, which inhibits HSV-1 replication, may act via NF-κB inhibition. Therefore, chemotherapeutic agents, which activate NF-κB, are not beneficial for HSV-1-induced oncolysis [65].

However, the enhancement of HSV-1 oncolytic activity can be obtained by combining HSV-1 with trichostatin A (TSA) [66]. TSA is an antitumor agent belonging to a histone deacetylase (HDAC) inhibitors, which change chromatin structure and act against skin cancer cells [67] and induce apoptosis [68]. For γ134.5 gene-deficient HSV-1 mutant R849 with lacZ encoding bacterial β-galactosidase substitution [69], it has been demonstrated that TSA, which enhances p65 acetylation and nuclear accumulation, promotes viral replication in oral squamous cell carcinoma (SCC) SAS cells. This effect results from TSA-driven enhancement of DNA binding by NF-κB during HSV-1 infection. As a consequence, the oncolytic activity of HSV-1 toward SCC can be improved [66].

The improvement of oncolytic HSV activity is also needed for malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive and may be associated with neurofibromatosis type 1 (NF1). Therefore, preclinical models are being developed [70]. Some therapeutic approaches may utilize NF-κB inhibitors in MPNSTs, where NF-κB is constitutively active and cells are resistant to oncolytic HSV. The possible role of NF-κB signaling in IFN-stimulated genes (ISGs) expression has led to the conclusion that using NF-κB inhibitors, such as TPCA-1, which decrease ISGs expression,
may improve productive infection of oncolytic HSV Δγ134.5 recombinants, which are devoid of ICP34.5 neurovirulence factor and whose replication is limited by protein kinase R (PKR) [71].

Another antitumor approach is based on UV-inactivated HSV-1 (UV-HSV-1), which is proposed for use as an adjuvant in donor mononuclear or NK cell infusions in acute myeloid leukemia therapy. UV-HSV-1 may induce cytolytic activity of human PBMCs and NK cells via TLR2/protein kinase C (PKC)/NF-κB, resulting in p65 nuclear translocation. This treatment results in leukemic cell killing [72].

5.1.3. PV

H-1 protoparvovirus (H-1PV), a member of Parvoviridae family, is a single-stranded (ss) DNA rodent pathogen and a promising OV, which can be administered by different routes. The main advantage of H-1PV is that it can cross the blood-brain barrier. H-1PV, whose replication is S-phase-dependent, evokes proinflammatory responses and is a hope for therapies of central nervous system tumors, including glioblastoma [73]. H-1PV armed with IL-2 can be used against lymphoma, glioma, colon, gastric cancer, neuroectodermal, pancreatic cancer, and others [25,73].

H-1PV’s role in oncolytic therapy could rely on immune priming and influencing maturation of DCs to exert antitumor immunity [74]. Human interdigitating DCs (iDCs), incubated with H-1PV-induced tumor cell lysates, exhibited increased expression of TLR3, TLR9, and NF-κB and produced higher amounts of TNF-α compared to uninfected human melanoma (SK29Mel) cells in ex vivo model [75].

In oncolytic therapy of pancreatic cancer, strategies of gene transfer involve introduction of a suicide therapeutic gene, which is missing or underexpressed in tumor cells. This approach allows obtaining a bystander effect of antitumor response toward neighboring cells [76]. Recombinant parvovirus rPVH1-yCD expressing the suicide gene yCD (yeast cytosine deaminase), which converts the prodrug 5-fluorocytosine (5-FC) into 5-FU, was tested as a novel strategy in gene-directed enzyme prodrug therapy against pancreatic cancer. In Panc1 and AsPc1 chemoresistant pancreatic cancer cells, wt H-1PV diminished the constitutive NF-κB activity. Moreover, NF-κB DNA binding and transcriptional activity were significantly reduced upon rPVH1-yCD/5-FC treatment. Importantly, the antitumor activity of wt H-1PV and rPVH1-yCD/5-FC is likely to be associated with attenuation of both NF-κB and Akt/phosphatidylinositol 3-kinase (PI3K) activity. Therefore, it is assumed that the oncolytic activity of H-1PV is linked to NF-κB. These observations suggest that inhibitors of these signaling pathways may increase the effectiveness of pancreatic cancer therapy [77].

5.2. RNA Viruses

5.2.1. Encephalomyocarditis Virus (EMCV)

Encephalomyocarditis virus (EMCV), belonging to Picornaviridae family, is a mammalian non-enveloped, positive sense-(+)ssRNA virus, which rarely infects humans [78,79]. In preclinical studies, EMCV oncolytic properties were implemented in the treatment of patients with CCRCC, which is well known for its high resistance to chemotherapy and radiation [79].

In CCRCC cells, EMCV virulence can be impaired by NF-κB suppression. In vitro studies on 786-O cell line treated with JSH-23, which inhibits LPS-induced NF-κB nuclear translocation, but not IκB degradation [80], demonstrated that JSH-23 significantly diminished LPS-induced NF-κB nuclear translocation, as well as susceptibility to EMCV virulence. Similarly, IKKγ-deficient 786-O cells showed resistance to EMCV virulence [79].

Importantly, both CCRCC and 786-O cells are characterized by von Hippel–Lindau (VHL), a tumor suppressor protein, inactivation. The loss of VHL results in hypoxia-inducible factor (HIF)-2α stabilization at tumor enhancers. Thus, CCRCC genes linked to tumorigenesis are upregulated [81]. VHL-null 786-O cells infected with EMCV did not show IFN-mediated antiviral response, but enhanced survival signaling under control of NF-κB and elevated viral replication. Since VHL is a negative
regulator of HIF, observed events can be a result of HIF-mediated promotion of NF-κB activation of the survival pathway. Thus, infected cells can be sensitized to virally induced cytotoxicity [79].

Importantly, the cross-talk between NF-κB signaling and IKK-regulated type I IFN gene expression is an obvious fact that implements the use of IKK inhibitors in oncolytic virotherapy. IKK-inhibitors, BMS-345541 [82] and TPCA-1 [83], counteract cell proliferation, p65 nuclear translocation, and NF-κB-regulated CXCL8 gene expression in glioma cells. Both inhibitors, when combined with OVs, such as EMCV, block IFN-regulated antiviral responses since the reversion of IFN-induced anticytopathic effect and antiviral effect by IKK inhibitors in glioma cells can be observed. Particularly, BMS-345541 inhibits the action of IFN against EMCV, which exert a CPE in U87 cells. Importantly, the correlation between this effect and suppression of NF-κB by BMS-345541 was observed [84].

5.2.2. M1 Alphavirus

M1 alphavirus, an ss(+)-RNA virus and a member of Togaviridae family, is an arthropod-borne pathogen, which promotes apoptosis of glioma cells. M1 displays high tumor tropism and oncolytic properties in vitro, in vivo, and ex vivo [85,86]. Particularly, in order to induce apoptosis, M1 targets zinc-finger antiviral protein (ZAP)-deficient tumor cells and acts via endoplasmic reticulum (ER) [86,87]. Cyclic adenosine monophosphate (cAMP) activation is required for tumor cell sensitization toward M1 [86].

When combining M1 with H89, a protein kinase A (PKA) [88] and NF-κB transcriptional inhibitor [89], the antiviral response is inhibited and M1-induced oncolysis is elevated. In addition, M1-induced NF-κB p65 phosphorylation is abolished in colon HCT-116 and Capan-1 cancer cell lines. This effect may result from the activation of exchange protein directly activated by cAMP isoform 1 (Epac1), which may either stabilize IκB or upregulate cellular oncogene Fos (c-Fos). c-Fos, in turn, interacts with NF-κB p65 and impairs its transcriptional activity [90]. Therefore, M1-induced ISGs expression can be abolished. Together, NF-κB has been shown to be involved in preventing type I IFN response by H89 [91].

5.2.3. Newcastle Disease Virus (NDV)

The Malaysian field outbreak isolate, NDV strain AF2240, is an avian pathogen and a member of ss(-)RNA Paramyxoviridae family. AF2240 is regarded as a good and efficient candidate in oncolytic virotherapy due to its high immunogenicity and selectivity toward tumors [92]. In tumor cells, NDV triggers innate and adaptive immune responses and exerts cytotoxic effect via caspase activation resulting in apoptosis [85]. What is important, ER stress upon NDV treatment induces antitumor immunity [64].

AF2240 triggers p38 mitogen-activated protein kinase phosphorylation upstream of IκBα processing and NF-κB nuclear translocation in 786-O cells. NF-κB, in turn, regulates IFN-β production in the early phase of NDV infection. In 786-O cells harboring VHL gene, the activity of NF-κB, IFN-β secretion, and killing effect was elevated upon NDV infection in comparison with 786-O cells. Interestingly, in NDV-infected 786-O cells treated with JSH-23, a canonical NF-κB signaling inhibitor [80], NF-κB activation was not completely abolished. Therefore, a cross-talk is assumed between canonical and non-canonical NF-κB signaling upon oncolytic respiratory syncytial virus (RSV) infection suggesting other regulatory mechanisms [93].

5.2.4. RV

RV is a human pathogen and enterotrope dsRNA virus belonging to Reoviridae family. RV is regarded as a good candidate for oncolytic treatment as an easily manufactured therapeutic agent, which has a stable genome and displays minimal toxicity for humans [94]. The ability of RV to use certain signaling pathways in transformed cells targeting constitutive Ras signaling makes it a good candidate as a drug against prostate cancer, glioma, MM, and pancreatic adenocarcinoma [25]. Indeed,
an RV-based oncolytic Reolysin (Oncolytics Biotech Inc., Calgary, AB, Canada) has been approved as an orphan drug by FDA in ovarian, fallopian tube cancers, glioma, gastric, and pancreatic cancer [44].

In HeLa cells, RV activates p65/p50 complexes [95]. Further studies have shown that at late times, post infection RV inhibits NF-κB activation. This type of dynamics of NF-κB regulation in RV-infected cells is required for TNF-α- and TRAIL-induced apoptosis [96].

In RV-infected cells, caspase 8-mediated apoptosis can be accelerated by glycogen synthase kinase (GSK)-3β inhibitors [97]. GSK-3β, which has an impact on NF-κB-regulated genes [98], can be inhibited by AR-A014418 [99], which also counteracts RV-induced NF-κB activation in HCT116 cells. Therefore, GSK-3β inhibitors could serve as therapeutic tools in NF-κB-mediated inflammation and cancer [97].

Nutlin-3a is another promising anticancer agent, which triggers p53 signaling in cells with wt p53 [100,101]. In p53+/− wt HCT116 and osteosarcoma U2OS cells treated with RV and nutlin-3a, increased NF-κB level and enhanced apoptosis were observed. NF-κB inhibition, in turn, resulted in reduced cell death in RV-infected and nutlin-3a treated wt HCT116 cells [102]. This observation demonstrated that cytotoxicity of RV combined with nutlin-3a relies upon NF-κB. Importantly, NF-κB activation depends on p53 [103]. NF-κB, in turn, controls p53 target genes [104]. Taken together, both p53 and NF-κB act synergistically to induce apoptosis. These interactions are important in therapeutic management of cancers expressing wt p53 [102].

RV activates NF-κB p65 nuclear translocation not only in p53+/− HCT116 cells, but also in cells lacking p53. Since NF-κB inhibition has a profound effect on reduction of cell death following RV infection, the enhancement of NF-κB activation to increase cell death was evaluated by combining RV and actinomycin-D (ActD) or etoposide (Etp) treatment of p53+/− cells. Increased oncolysis observed may also be a consequence of upregulation of p21-encoding cyclin-dependent kinase inhibitor 1 (CDKN1A) gene [105], whose regulation depends on NF-κB [106].

Although RV-induced oncolysis has been implemented in clinical trials, the mechanisms of this process are still not fully elucidated. In breast cancer treatment studies, NF-κB has been investigated as a factor, which either promotes or suppresses apoptosis of tumor cells [107]. RV infection of MCF7 and hypotriploid HTB133 cells upregulated p65 NF-κB expression, as well as its nuclear translocation and DNA binding. NF-κB inhibition, in turn, resulted in oncolytic protection and downregulation of p53-upregulated modulator of apoptosis (PUMA) expression. This study suggests that in breast cancer therapy, NF-κB acts proapoptotically, mediates RV-induced oncolysis, and may serve as a predictive indicator of the sensitivity to RV treatment [108].

5.2.5. RSV

RSV, a member of Paramyxoviridae family, is an ss(-)RNA virus, which is regarded as an oncolytic agent. However, the data on the effect of RSV on apoptosis in individual cell types are, in fact, conflicting. Nevertheless, the oncolytic potential of RSV toward certain tumors, including skin neoplasm, has been demonstrated [109].

As shown in human prostate tumor xenografts, RSV leads to oncolysis of prostatic cancer cells in vitro and in vivo. In PC-3 cells, RSV-induced apoptosis via an intrinsic pathway that involves caspase-3. NF-κB downregulation, observed upon RSV infection, results in the upregulation of pro-apoptotic genes and downregulation of anti-apoptotic genes. Consequently, apoptosis and oncolysis can be observed [110].

Further studies demonstrated that RSV-induced modulation of innate antiviral response is linked to androgen dependence and/or androgen receptor expression on target cells. PC-3 cells, which are androgen-independent, are susceptible to RSV-induced apoptosis despite functional IFN-mediated antiviral signaling, but a defective NF-κB response. Importantly, defective NF-κB activation could not be observed in androgen-sensitive LNCaP and RWPE-1 prostate cancer cells [111].
5.2.6. VSV

VSV is a non-segmented ss(-)RNA virus, belonging to *Rhabdoviridae* family, infecting insects and livestock animals. Preexisting immunity against VSV in humans, as well as cell-cycle-independent cytoplasmic replication cycle without risk of host cell transformation in various cell lines, renders VSV a promising tool for oncolytic virotherapy [112]. Importantly, high sensitivity of VSV to IFN response favors it as a candidate for the treatment of tumors with aberrant IFN signaling. Nevertheless, VSV may also target tumors with abnormal function of Ras, p53, and myelocytomatosis (Myc) proteins [85].

The importance of IKK/NF-κB signaling in type I IFN-mediated antiviral response has been demonstrated in glioma cell lines. Both TPCA-1, an IKKβ inhibitor, which prevents IκBα phosphorylation [83], and a selective IKKα/IKKβ inhibitor, BMS-345541 [82], have been proposed in combination with VSV for anticancer therapies. In glioma cells, TPCA-1 and BMS-345541 inhibited NF-κB activation and *CXCL8* gene expression, as well as IFN-activated gene expression. BMS-345541 has been demonstrated to counteract antiviral IFN effect against VSV in glioma cells since VSV is considered as a promising tool in oncolytic therapies of malignant brain tumors. Importantly, this effect correlated with decreased NF-κB activity [84].

The oncolytic potential of VSV can also be modulated by vorinostat [113], a histone deacetylase inhibitor [114], which modulates NF-κB-dependent genes [115]. Vorinostat increases p65 NF-κB nuclear accumulation, DNA binding, and acetylation, while inhibiting IFN signaling in PC-3 cells. Subsequent NF-κB activation also induces certain genes linked to autophagy. Together, vorinostat enhances VSV replication in PC-3 cells and oncolysis. The effect of vorinostat on NF-κB signaling, autophagy, and oncolysis in VSV-infected cells was also demonstrated in DU145 prostate cell line and HCT116 cells [113]. Other studies have shown the synergy of curcumin, an anti-inflammatory agent and NF-κB inhibitor [116] and VSV infection in enhancing oncolysis of PC-3 cells. When treated with curcumin and then infected with recombinant M protein mutant VSV, rM51R-M, the cells became sensitized to VSV-induced apoptosis and showed the reduction on phospho (p)-NF-κB expression. At the same time, the decrease in NF-κB-dependent anti-apoptotic Bcl-extra-large (xL) protein content was observed [117].

NF-κB signaling is involved in MM development [2]. NF-κB activity is also induced by VSV infection of myeloma cells and may promote apoptosis and virus spread. On the contrary, NF-κB plays a prosurvival role during VSV infection to ensure viral replication. Inhibition of NF-κB by BMS-345541 led to attenuation of VSV replication in U266 and 5TGM1 MM cell lines. Bortezomib, a proteasomal inhibitor [118], which inhibits IκBα degradation and p65 nuclear accumulation [119], counteracted virally induced p65 nuclear protein expression in U266 nuclear extracts. Therefore, antagonistically acting bortezomib may not be profitable for the virus spread. Despite no effect on the increase of VSV titer upon NF-κB in vitro, in vivo studies in mouse MM model have shown that bortezomib is not able to inhibit intratumoral replication of VSV. Moreover, bortezomib enhances the therapeutic effect of oncolytic VSV [120] armed with murine IFN-β and NIS VSV-IFNβ-NIS [121].

6. Conclusions

Oncolytic virotherapy is a new promising therapeutic approach, which needs improvement to enhance the antitumor effect. Therefore, combined therapies using immunomodulating drugs, including NF-κB regulators, are considered in the treatments. The importance of the complexity of NF-κB activation in tumor cells and the interplay between OVs and NF-κB signaling is shown in this review. Since NF-κB is a key player in tumorigenesis, which shapes the cellular response and plays a role in balancing the immune system, NF-κB activation level should be considered in oncolytic treatment. Thus, NF-κB activation level can indicate the efficacy and effectiveness of novel therapeutic approaches and help obtain the desired therapeutic effect.

**Author Contributions:** J.S. contributed to conceptualization and writing (original draft preparation, review and editing). L.S.-D. contributed to conceptualization and writing (figure preparation, review and editing).
**Funding:** This work was funded by National Science Centre, Poland, grant number UMO-2015/19/D/NZ6/02873.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Jing, H.; Lee, S. NF-κB in cellular senescence and cancer treatment. *Mol. Cells* **2014**, *37*, 189–195. [CrossRef] [PubMed]

2. Li, F.; Zhang, J.; Arfuso, F.; Chinnathambi, A.; Zayed, M.E.; Alharbi, S.A.; Kumar, A.P.; Ahn, K.S.; Sethi, G. NF-κB in cancer therapy. *Arch. Toxicol.* **2015**, *89*, 711–731. [CrossRef] [PubMed]

3. Park, M.H.; Hong, J.T. Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches. *Cells* **2016**, *5*, 15. [CrossRef] [PubMed]

4. Pires, B.R.B.; Silva, R.C.M.C.; Ferreira, G.M.; Abdelhay, E. NF-κB: Two sides of the same coin. *Genes* **2018**, *9*, 24. [CrossRef] [PubMed]

5. Mitchell, S.; Vargas, J.; Hoffmann, A. Signaling via the NFκB system. *Wiley Interdiscip. Rev. Syst. Biol. Med.* **2016**, *8*, 227–241. [CrossRef] [PubMed]

6. Hayden, M.S.; Ghosh, S. NF-κB, the first quarter-century: Remarkable progress and outstanding questions. *Genes Dev.* **2012**, *26*, 203–234. [CrossRef] [PubMed]

7. Sun, S.-C. Non-canonical NF-κB signaling pathway. *Cell Res.* **2011**, *21*, 71–85. [CrossRef] [PubMed]

8. Sun, S.-C. The noncanonical NF-κB pathway. *Immunol. Rev.* **2012**, *246*, 125–140. [CrossRef] [PubMed]

9. Espinosa, L.; Bigas, A.; Mulero, M.C. Alternative nuclear functions for NF-κB family members. *Am. J. Cancer Res.* **2011**, *1*, 446–459. [PubMed]

10. Hoesel, B.; Schmid, J.A. The complexity of NF-κB signaling in inflammation and cancer. *Mol. Cancer* **2013**, *12*, 86. [CrossRef] [PubMed]

11. Shih, V.F.-S.; Tsui, R.; Caldwell, A.; Hoffmann, A. A single NFκB system for both canonical and non-canonical signaling. *Cell Res.* **2011**, *21*, 86–102. [CrossRef] [PubMed]

12. Zarnegar, B.; Yamazaki, S.; He, J.Q.; Cheng, G. Control of canonical NF-κB activation through the NIK-IKK complex pathway. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 3503–3508. [CrossRef] [PubMed]

13. Zeligs, K.P.; Neuman, M.K.; Annunziata, C.M. Molecular pathways: The balance between cancer and the immune system challenges the therapeutic specificity of targeting nuclear factor-κB signaling for cancer treatment. *Clin. Cancer Res.* **2016**, *22*, 4302–4308. [CrossRef] [PubMed]

14. Taniguchi, K.; Karin, M. NF-κB, inflammation, immunity and cancer: Coming of age. *Nat. Rev. Immunol.* **2018**, *18*, 309–324. [CrossRef] [PubMed]

15. Geismann, C.; Erhart, W.; Grohmann, F.; Schreiber, S.; Schneider, G.; Schäfer, H.; Arlt, A. TRAIL/NF-κB/CX3CL1 mediated onco-immuno crosstalk leading to TRAIL resistance of pancreatic cancer cell lines. *Int. J. Mol. Sci.* **2018**, *19*, 1661. [CrossRef] [PubMed]

16. Geismann, C.; Grohmann, F.; Dreher, A.; Häslar, R.; Rosenstiel, P.; Legler, K.; Hauser, C.; Egberts, J.H.; Sipos, B.; Schreiber, S.; et al. Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer. *Biochim. Biophys. Acta Mol. Cell Res.* **2017**, *1864*, 782–796. [CrossRef] [PubMed]

17. Riedlinger, T.; Haas, J.; Busch, J.; van de Sluis, B.; Kracht, M.; Schmitz, M.L. The direct and indirect roles of NF-κB in cancer: Lessons from oncogenic fusion proteins and knock-in mice. *Biomedicines* **2018**, *6*, 36. [CrossRef] [PubMed]

18. Awasthee, N.; Rai, V.; Chava, S.; Nallasamy, P.; Kunnumakkara, A.B.; Bishayee, A.; Chauban, S.C.; Challagundla, K.B.; Gupta, S.C. Targeting IκB kinases for cancer therapy. *Semin. Cancer Biol.* **2018**, *26*, 209–221. [CrossRef] [PubMed]

19. Colomer, C.; Marruecos, L.; Vert, A.; Bigas, A.; Espinosa, L. NF-κB-independent roles in cancer. *Biomedicines* **2017**, *5*, 26. [CrossRef] [PubMed]

20. Zhao, J.; He, S.; Minassian, A.; Li, J.; Feng, P. Recent advances on viral manipulation of NF-κB signaling pathway. *Curr. Opin. Virol.* **2015**, *15*, 103–111. [CrossRef] [PubMed]

21. Baldwin, A.S. Regulation of cell death and autophagy by IKK and NF-κB: Critical mechanisms in immune function and cancer. *Immunol. Rev.* **2012**, *246*, 327–345. [CrossRef] [PubMed]

22. Gujar, S.; Pol, J.G.; Kim, Y.; Lee, P.W.; Kroemer, G. Antitumor benefits of antiviral immunity: An underappreciated aspect of oncolytic virotherapies. *Trends Immunol.* **2018**, *39*, 209–221. [CrossRef] [PubMed]
23. Hamid, O.; Hoffner, B.; Gasal, E.; Hong, J.; Carvajal, R.D. Oncolytic immunotherapy: Unlocking the potential of viruses to help target cancer. *Cancer Immunol. Immunother.* 2017, 66, 1249–1264. [CrossRef] [PubMed]

24. Fukuhara, H.; Ino, Y.; Todo, T. Oncolytic virus therapy: A new era of cancer treatment at dawn. *Cancer Sci.* 2016, 107, 1373–1379. [CrossRef] [PubMed]

25. Maroun, J.; Muñoz-Alia, M.; Ammayappan, A.; Schulze, A.; Peng, K.-W.; Russell, S. Designing and building oncolytic viruses. *Future Virol.* 2017, 12, 193–213. [CrossRef] [PubMed]

26. Martin, N.T.; Bell, J.C. Oncolytic virus combination therapy: Killing one bird with two stones. *Mol. Ther.* 2018, 26, 1414–1422. [CrossRef] [PubMed]

27. Jhawar, S.R.; Thandoni, A.; Bommareddy, P.K.; Hassan, S.; Kohlhapp, F.J.; Goyal, S.; Schenkel, J.M.; Silk, A.W.; Zloza, A. Oncolytic viruses—natural and genetically engineered cancer immunotherapies. *Front. Oncol.* 2017, 7, 202. [CrossRef] [PubMed]

28. Meyers, D.E.; Wang, A.A.; Thirukkumaran, C.M.; Morris, D.G. Current immunotherapeutic strategies to enhance oncolytic virotherapy. *Front. Oncol.* 2017, 7, 114. [CrossRef] [PubMed]

29. Haanen, J.B.A.G. Converting cold into hot tumors by combining immunotherapies. *Cell* 2017, 170, 1055–1056. [CrossRef] [PubMed]

30. Badalamenti, G.; Fanale, D.; Incorvaia, L.; Barraco, N.; Listi, A.; Maraglino, R.; Vincenzi, B.; Calò, V.; Iovanna, J.L.; Bazan, V.; et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? *Cell. Immunol.* 2018. [CrossRef] [PubMed]

31. Sackstein, R.; Schatton, T.; Barthel, S.R. T-lymphocyte homing: An underappreciated yet critical hurdle for successful cancer immunotherapy. *Lab. Invest.* 2017, 97, 669–697. [CrossRef] [PubMed]

32. Fournier, C.; Martin, F.; Zitvogel, L.; Kroemer, G.; Galluzzi, L.; Apetoh, L. Trial Watch: Adoptively transferred cells for anticancer immunotherapy. *Onc-immunology* 2017, 6, e1363139. [CrossRef] [PubMed]

33. Met, Ö.; Jensen, K.M.; Chamberlain, C.A.; Donia, M.; Svane, I.M. Principles of adoptive T cell therapy in cancer. *Semin. Immunopathol.* 2018, 1–10. [CrossRef] [PubMed]

34. Kershaw, M.H.; Wang, G.; Westwood, J.A.; Pachynski, R.K.; Tiffany, H.L.; Marincola, F.M.; Wang, E.; Young, H.A.; Murphy, P.M.; Hwu, P. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. *Hum. Gene Ther.* 2002, 13, 1971–1980. [CrossRef] [PubMed]

35. Zhang, L.; Yu, Z.; Muranski, P.; Palmer, D.C.; Restifo, N.P.; Rosenberg, S.A.; Morgan, R.A. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. *Gene Ther.* 2013, 20, 575–580. [CrossRef] [PubMed]

36. Seidel, J.A.; Otsuka, A.; Kabashima, K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. *Front. Oncol.* 2018, 8, 86. [CrossRef] [PubMed]

37. Andtbacka, R.; Curti, B.D.; Hallmeyer, S.; Feng, Z.; Paustian, C.; Bifulco, C.; Fox, B.; Grose, M.; Shafren, D. Phase II calm extension study: Cossackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment. *J. Immunother. Cancer* 2015, 3 (Suppl. 2), P343. [CrossRef] [PubMed]

38. Alemany, R. Oncolytic adenoviruses in cancer treatment. *Biomedicines* 2014, 2, 36–49. [CrossRef] [PubMed]

39. Yamamoto, Y.; Nagasato, M.; Yoshida, T.; Aoki, K. Recent advances in genetic modification of adenovirus vectors for cancer treatment. *Cancer Sci.* 2017, 108, 831–837. [CrossRef] [PubMed]

40. Liang, M. Oncorine, the world first oncolytic virus medicine and its update in China. *Curr. Cancer Drug Targets* 2018, 18, 171–176. [CrossRef] [PubMed]

41. Debbas, M.; White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. *Genes Dev.* 1993, 7, 546–554. [CrossRef] [PubMed]

42. Pilder, S.; Moore, M.; Logan, J.; Shenk, T. The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. *Mol. Cell. Biol.* 1986, 6, 470–476. [CrossRef] [PubMed]

43. Baker, A.T.; Aguirre-Hernández, C.; Halldén, G.; Parker, A.L. Designer oncolytic adenovirus: Coming of age. *Cancers* 2018, 10, 201. [CrossRef] [PubMed]

44. De Munck, J.; Binks, A.; McNeill, I.A.; Aerts, J.L. Oncolytic virus-induced cell death and immunity: A match made in heaven? *J. Leukoc. Biol.* 2017, 102, 631–643. [CrossRef] [PubMed]

45. Kuryk, L.; Moller, A.W.; Garofalo, M.; Cerullo, V.; Pesonen, S.; Alemany, R.; Jaderberg, M. Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model. *J. Med. Virol.* 2018, 90, 1669–1673. [CrossRef] [PubMed]
46. Vassilev, L.; Ranki, T.; Joensuu, T.; Jäger, E.; Karbach, J.; Wahle, C.; Partanen, K.; Kairemo, K.; Alanko, T.; Turkkì, R.; et al. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. *Oncoimmunology* 2015, 4, e1017702. [CrossRef] [PubMed]

47. Ranki, T.; Pesonen, S.; Hemminki, A.; Partanen, K.; Kairemo, K.; Alanko, T.; Lundin, J.; Linder, N.; Turkkì, R.; Ristimäki, A.; et al. Phase I study with ONCOS-102 for the treatment of solid tumors—An evaluation of clinical response and exploratory analyses of immune markers. *J. Immunother. Cancer* 2016, 4, 17. [CrossRef] [PubMed]

48. Fukuda, K.; Abei, M.; Ugai, H.; Seo, E.; Wakayama, M.; Murata, T.; Todoroki, T.; Tanaka, N.; Hamada, H.; Yokoyama, K.K. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. *Cancer Res.* 2003, 63, 4434–4440. [PubMed]

49. Yamada, K.; Moriyama, H.; Yasuda, H.; Hara, K.; Maniwa, Y.; Hamada, H.; Yokono, K.; Nagata, M. Modification of the Rb-binding domain of replication-competent adenoviral vector enhances cytotoxicity against human esophageal cancers via NF-κB activity. *Hum. Gene Ther.* 2007, 18, 389–400. [CrossRef] [PubMed]

50. Yamano, S.; Tokino, T.; Yasuda, M.; Kaneeuchi, M.; Takahashi, M.; Nitsu, Y.; Fujinaga, K.; Yamashita, T. Induction of transformation and p53-dependent apoptosis by adenovirus type 5 E4orf6/7 cDNA. *J. Virol.* 1999, 73, 10095–10103. [PubMed]

51. Passaro, C.; Borriello, F.; Vastolo, V.; Di Somma, S.; Scamardella, E.; Gigantino, V.; Franco, R.; Marone, G.; Portella, G. The oncolytic virus d922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. *Oncotarget* 2016, 7, 1500–1515. [CrossRef] [PubMed]

52. Wennier, S.; Li, S.; McFadden, G. Oncolytic virotherapy for pancreatic cancer. *Expert Rev. Mol. Med.* 2011, 13, e18. [CrossRef] [PubMed]

53. Maliandi, M.V.; Mato-Berciano, A.; Sobrevalls, L.; Roué, G.; José, A.; Fillat, C. AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation. *Mol. Cancer* 2015, 14, 146. [CrossRef] [PubMed]

54. Cheng, P.-H.; Wechman, S.L.; McMasters, K.M.; Zhou, H.S. Oncolytic replication of Elb-deleted adenoviruses. *Viruses* 2015, 7, 5767–5779. [CrossRef] [PubMed]

55. Palmer, D.H.; Chen, M.-J.; Searle, P.F.; Kerr, D.J.; Young, L.S. Inhibition of NF-κB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy. *Gene Ther.* 2005, 12, 1187–1197. [CrossRef] [PubMed]

56. Schack, J.; Bennett, M.L.; Colbert, J.D.; Torres, A.V.; Clayton, G.H.; Ornelles, D.; Moorhead, J. E1A and E1B proteins inhibit inflammation induced by adenovirus. *Proc. Natl. Acad. Sci. USA* 2004, 101, 3124–3129. [CrossRef] [PubMed]

57. Radke, J.R.; Grigera, F.; Ucker, D.S.; Cook, J.L. Adenovirus E1B 19-kilodalton protein modulates innate immunity through apoptotic mimicry. *J. Virol.* 2014, 88, 2658–2669. [CrossRef] [PubMed]

58. Cerullo, V.; Diaconu, I.; Romano, V.; Hirvinen, M.; Ugolini, M.; Escutenaire, S.; Holm, S.-L.; Kipar, A.; Kanerva, A.; Hemminki, A. An oncolytic adenovirus enhanced for Toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. *Mol. Ther.* 2012, 20, 2076–2086. [CrossRef] [PubMed]

59. Capasso, C.; Hirvinen, M.; Garofalo, M.; Romanik, D.; Kuryk, L.; Sarvela, T.; Vitale, A.; Antopolosky, M.; Magarkar, A.; Viitala, T.; et al. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. *Oncoimmunology* 2015, 5, e1105429. [CrossRef] [PubMed]

60. Garofalo, M.; Iovine, B.; Kuryk, L.; Capasso, C.; Hirvinen, M.; Vitale, A.; Yliperttula, M.; Bevilacqua, M.A.; Cerullo, V. Oncolytic adenovirus loaded with L-carnosine as novel strategy to enhance the antitumor activity. *Mol. Cancer Ther.* 2016, 15, 651–660. [CrossRef] [PubMed]

61. Garofalo, M.; Saari, H.; Somersalo, P.; Crescenti, D.; Kuryk, L.; Aksela, L.; Capasso, C.; Madetoja, M.; Koskinen, K.; Oksanen, T.; et al. Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment. *J. Control. Release* 2018, 283, 223–234. [CrossRef] [PubMed]

62. Sanchala, D.S.; Bhatt, L.K.; Prabhavalkar, K.S. Oncolytic herpes simplex viral therapy: A stride toward selective targeting of cancer cells. *Front. Pharmacol.* 2017, 8, 270. [CrossRef] [PubMed]
63. Sokolowski, N.A.S.; Rizos, H.; Diefenbach, R.J. Oncolytic virotherapy using herpes simplex virus: How far have we come? Oncolytic Virot. 2015, 4, 207–219. [CrossRef] [PubMed]

64. Fountzilas, C.; Patel, S.; Mahalingam, D. Review: Oncolytic virotherapy, updates and future directions. Oncotarget 2017, 8, 102617–102639. [CrossRef] [PubMed]

65. Kulu, Y.; Kawasaki, H.; Donahue, J.M.; Kasuya, H.; Cusack, J.C.; Choi, E.W.; Kuruppu, D.K.; Fuchs, B.C.; Tanabe, K.K. Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis. Cancer Gene Ther. 2013, 20, 133–140. [CrossRef] [PubMed]

66. Katsura, T.; Iwai, S.; Ota, Y.; Shimizu, H.; Ikuta, K.; Yura, Y. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells. Cancer Gene Ther. 2009, 16, 237–245. [CrossRef] [PubMed]

67. Saunders, N.; Dicker, A.; Popa, C.; Jones, S.; Dahler, A. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res. 1999, 59, 399–404. [PubMed]

68. Minucci, S.; Horn, V.; Bhattacharyya, N.; Russanova, V.; Ogryzko, V.V.; Gabriele, L.; Howard, B.H.; Ozato, K. A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc. Natl. Acad. Sci. USA 1997, 94, 11295–11300. [CrossRef] [PubMed]

69. Andreansky, S.; Soroceanu, L.; Flotte, E.R.; Chou, J.; Markert, J.M.; Gillespie, G.Y.; Roizman, B.; Whitley, R.J. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 1997, 57, 1502–1509. [PubMed]

70. Antoszczyk, S.; Spyra, M.; Mautner, V.F.; Kurtz, A.; Stemmer-Rachamimov, A.O.; Martuza, R.L.; Rabkin, S.D. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro Oncol. 2014, 16, 1057–1066. [CrossRef] [PubMed]

71. Jackson, J.D.; Markert, J.M.; Li, L.; Carroll, S.L.; Cassady, K.A. STAT1 and NF-kB inhibitors diminish basal interferon-stimulated gene expression and improve the productive infection of oncolytic HSV in MPNST cells. Mol. Cancer Res. 2016, 14, 482–492. [CrossRef] [PubMed]

72. Samudio, I.; Rezvani, K.; Shaim, H.; Ngom, M.; Bu, L.; Liu, G.; Lee, J.T.C.; Imren, S.; Lam, V.; et al. UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells. Blood 2016, 127, 2575–2586. [CrossRef] [PubMed]

73. Angelova, A.L.; Barf, M.; Geletneky, K.; Unterberg, A.; Rommelaere, J. Immunotherapeutic potential of oncolytic H-1 parvovirus: Hints of glioblastoma microenvironment conversion towards immunogenicity. Viruses 2017, 9, 382. [CrossRef] [PubMed]

74. Moehler, M.H.; Zeidler, M.; Wilberg, V.; Cornelis, J.J.; Woelfel, T.; Rommelaere, J.; Galle, P.R.; Heike, M. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum. Gene Ther. 2005, 16, 996–1005. [CrossRef] [PubMed]

75. Sieben, M.; Schäfer, P.; Dinsart, C.; Galle, P.R.; Moehler, M. Activation of the human immune system via Toll-like receptors by the oncolytic parvovirus H-1. Int. J. Cancer 2013, 132, 2548–2556. [CrossRef] [PubMed]

76. Rouanet, M.; Lebrin, M.; Gross, F.; Bournet, B.; Cordelier, P.; Buscail, L. Gene therapy for pancreatic cancer: Specificity, issues and hopes. Int. J. Mol. Sci. 2017, 18, 1231. [CrossRef] [PubMed]

77. Réjiba, S.; Bigand, C.; Parmentier, C.; Masmoudi, A.; Hajri, A. Oncosuppressive suicide gene virotherapy “PVH1-yCD/5-FC” for pancreatic peritoneal carcinomatosis treatment: NFκB and Akt/PI3K involvement. PLoS ONE 2013, 8, e70594. [CrossRef] [PubMed]

78. Carocci, M.; Bakkali-Kassi, L. The encephalomyocarditis virus. Virulence 2012, 3, 351–367. [CrossRef] [PubMed]

79. Roos, F.C.; Roberts, A.M.; Hwang, I.L.; Moriyama, E.H.; Evans, A.J.; Sybingco, S.; Watson, I.R.; Carneiro, L.A.M.; Gedye, C.; Girardin, S.E.; et al. Oncolytic targeting of renal cell carcinoma via oncolyticencephalomyocarditis virus. EMBO Mol. Med. 2010, 2, 275–288. [CrossRef] [PubMed]

80. Shin, H.-M.; Kim, M.-H.; Kim, B.H.; Jung, S.-H.; Kim, Y.S.; Park, H.J.; Hong, J.T.; Min, K.R.; Kim, Y. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kB without affecting IkB degradation. FEBs Lett. 2004, 571, 50–54. [CrossRef] [PubMed]

81. Yao, X.; Tan, J.; Lim, K.J.; Koh, J.; Ooi, W.F.; Li, Z.; Huang, D.; Xing, M.; Chan, Y.S.; Qu, J.Z.; et al. VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 2017, 7, 1284–1305. [CrossRef] [PubMed]
82. Burke, J.R.; Pattoli, M.A.; Gregor, K.R.; Brassil, P.J.; MacMaster, J.F.; McIntyre, K.W.; Yang, X.; Iotzova, V.S.; Clarke, W.; Strnad, J.; et al. BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. *J. Biol. Chem.* 2003, 278, 1450–1456. [CrossRef] [PubMed]

83. Podolin, P.L.; Callahan, J.F.; Bolognese, B.J.; Li, Y.H.; Carlson, K.; Davis, T.G.; Mellow, G.W.; Evans, C.; Roshak, A.K. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[[Aminocarbonyl]amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. *J. Pharmacol. Exp. Ther.* 2005, 312, 373–381. [CrossRef] [PubMed]

84. Du, Z.; Whitt, M.A.; Baumann, J.; Garner, J.M.; Morton, C.L.; Davidoff, A.M.; Pfeffer, L.M. Inhibition of type

85. Huang, F.; Wang, B.-R.; Wu, Y.-Q.; Wang, F.-C.; Zhang, J.; Wang, Y.-G. Oncolytic viruses against cancer stem

86. Lundstrom, K. Oncolytic alphaviruses in cancer immunotherapy. *Vaccines* 2017, 5, 9. [CrossRef] [PubMed]

87. Lundstrom, K. New frontiers in oncolytic viruses: Optimizing and selecting for virus strains with improved
efficacy. *Biologics* 2018, 12, 43–60. [CrossRef] [PubMed]

88. Chijiwa, T.; Mishima, A.; Hagiwara, M.; Sano, M.; Hayashi, K.; Inoue, T.; Naito, K.; Toshioka, T.; Hidaka, H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89), of PC12D pheochromocytoma cells. *J. Biol. Chem.* 1990, 265, 5267–5272. [PubMed]

89. Muroi, M.; Suzuki, T. Role of protein kinase A in LPS-induced activation of NF-κB proteins of a mouse macrophage-like cell line, J774. *Cell. Signal.* 1993, 5, 289–298. [CrossRef]

90. Koga, K.; Takaesu, G.; Yoshida, R.; Nakaya, M.; Kobayashi, T.; Kinjyo, I.; Yoshimura, A. Cyclic adenosine
monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. *Immunity* 2009, 30, 372–383. [CrossRef] [PubMed]

91. Li, K.; Liang, J.; Lin, Y.; Zhang, H.; Xiao, X.; Tan, Y.; Cai, J.; Zhu, W.; Xing, F.; Hu, J.; et al. A classical PKA inhibitor increases the oncolytic effect of M1 virus through activation of exchange protein directly activated by cAMP 1. *Oncotarget* 2016, 7, 48443–48455. [CrossRef] [PubMed]

92. Kalyanasundram, J.; Hamid, A.; Yusoff, K.; Chia, S.L. Newcastle disease virus strain AF2240 as an oncolytic virus: A review. *Acta Trop.* 2018, 183, 126–133. [CrossRef] [PubMed]

93. Ch’ng, W.-C.; Abd-Aziz, N.; Ong, M.-H.; Stanbridge, E.J.; Shafee, N. Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/1κBα pathway. *Cell. Oncol.* 2015, 38, 279–288. [CrossRef] [PubMed]

94. Thirukkumaran, C.; Morris, D.G. Oncolytic viral therapy using reovirus. *Methods Mol. Biol.* 2015, 1317, 187–223. [CrossRef] [PubMed]

95. Connolly, J.L.; Rodgers, S.E.; Clarke, P.; Ballard, D.W.; Kerr, L.D.; Tyler, K.L.; Dermody, T.S. Reovirus-induced apoptosis requires activation of transcription factor NF-κB. *J. Virol.* 2000, 74, 2981–2989. [CrossRef] [PubMed]

96. Clarke, P.; Meintzer, S.M.; Moffitt, L.A.; Tyler, K.L. Two distinct phases of virus-induced nuclear factor κB regulation enhance tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in virus-infected cells. *J. Biol. Chem.* 2003, 278, 18092–18100. [CrossRef] [PubMed]

97. Min, H.-J.; Koh, S.S.; Cho, I.-R.; Srisuttee, R.; Park, E.-H.; Jhun, B.H.; Kim, Y.-G.; Oh, S.; Kwak, J.E.; Johnston, R.N.; et al. Inhibition of GSK-3β enhances reovirus-induced apoptosis in colon cancer cells. *Int. J. Oncol.* 2009, 35, 617–624. [CrossRef] [PubMed]

98. Ougolkov, A.V.; Fernandez-Zapico, M.E.; Savoy, D.N.; Urrutia, R.A.; Billadeau, D.D. Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. *Cancer Res.* 2005, 65, 2076–2081. [CrossRef] [PubMed]

99. Bhat, R.; Xue, Y.; Berg, S.; Hellberg, S.; Ormö, M.; Nilssson, Y.; Radesätter, A.-C.; Jerning, E.; Markgren, P.-O.; Borgegård, T.; et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. *J. Biol. Chem.* 2003, 278, 45937–45945. [CrossRef] [PubMed]
100. Vassilev, L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. *Science* **2004**, *303*, 844–848. [CrossRef] [PubMed]

101. Carvajal, D.; Tovar, C.; Yang, H.; Vu, B.T.; Heimbrook, D.C.; Vassilev, L.T. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. *Cancer Res.* **2005**, *65*, 1918–1924. [CrossRef] [PubMed]

102. Pan, D.; Pan, L.-Z.; Hill, R.; Marcato, P.; Shmulevitz, M.; Vassilev, L.T.; Lee, P.W.K. Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation. *Br. J. Cancer* **2011**, *105*, 1012–1022. [CrossRef] [PubMed]

103. Ravi, R.; Mookerjee, B.; van Hensbergen, Y.; Bedi, G.C.; Giordano, A.; El-Deiry, W.S.; Fuchs, E.J.; Bedi, A. p53-mediated repression of nuclear factor-κB RelA via the transcriptional integrator p300. *Cancer Res.* **1998**, *58*, 4531–4536. [PubMed]

104. Wu, H.; Lozano, G. NF-κB activation of p53. A potential mechanism for suppressing cell growth in response to stress. *J. Biol. Chem.* **1994**, *269*, 20067–20074. [PubMed]

105. Pan, D.; Marcato, P.; Ahn, D.-G.; Gujar, S.; Pan, L.-Z.; Shmulevitz, M.; Lee, P.W.K. Activation of p53 by chemotherapeutic agents enhances reovirus oncoslysis. *PLoS ONE* **2013**, *8*, e54006. [CrossRef] [PubMed]

106. Basile, J.R.; Eichten, A.; Zaczny, V.; Münger, K. NF-κB-mediated induction of p21Cip1/Waf1 by tumor necrosis factor α induces growth arrest and cytoprotection in normal human keratinocytes. *Mol. Cancer Res.* **2004**, *2*, 262–270. [PubMed]

107. Park, Y.H. The nuclear factor-κB pathway and response to treatment in breast cancer. *Pharmacogenomics* **2017**, *18*, 1697–1709. [PubMed]

108. Thirukkumaran, C.; Shi, Z.-Q.; Thirukkumaran, P.; Luider, J.; Kopciuk, K.; Spurrell, J.; Elzinga, K.; Morris, D. PUMA and NF-κB are cell signaling predictors of reovirus oncoslysis of breast cancer. *PLoS ONE* **2017**, *12*, e0168233. [CrossRef] [PubMed]

109. Salimi, V.; Tavakoli-Yaraki, M.; Mahmoudi, M.; Shahabi, S.; Gharaogzolou, M.J.; Shokri, F.; Mokhtari-Azad, T. The oncolytic effect of respiratory syncytial virus (RSV) in human skin cancer cell line, A431. *Iran. Red Crescent Med. J.* **2013**, *15*, 62–67. [CrossRef] [PubMed]

110. Echchgadda, I.; Kota, S.; DeLa Cruz, I.; Sabbah, A.; Chang, T.; Harnack, R.; Mgbemena, V.; Chatterjee, B.; Bose, S. Anticancer oncolytic activity of respiratory syncytial virus. *Cancer Gene Ther.* **2009**, *16*, 923–935. [CrossRef] [PubMed]

111. Echchgadda, I.; Chang, T.-H.; Sabbah, A.; Bakri, I.; Ikono, Y.; Hubbard, G.B.; Chatterjee, B.; Bose, S. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): Consequences of deficient interferon-dependent antiviral defense. *BMC Cancer* **2011**, *11*, 43. [CrossRef] [PubMed]

112. Felt, S.A.; Grdzelishvili, V.Z. Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: A 5-year update. *J. Gen. Virol.* **2017**, *98*, 2895–2911. [CrossRef] [PubMed]

113. Shulak, L.; Beljanski, V.; Chiang, C.; Dutta, S.M.; Van Grevenynghe, J.; Belgnaoui, S.; Nguyen, T.L.-A.; Di Lenardo, T.; Semmes, O.J.; Lin, R.; et al. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncoslysis in prostate cancer cells by modulating NF-κB-dependent autophagy. *J. Virol.* **2014**, *88*, 2927–2940. [CrossRef] [PubMed]

114. Richon, V.M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind, R.A.; Marks, P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 3003–3007. [CrossRef] [PubMed]

115. Liu, Y.; Denlinger, C.E.; Rundall, B.K.; Smith, P.W.; Jones, D.R. Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. *J. Biol. Chem.* **2006**, *281*, 31359–31368. [CrossRef] [PubMed]

116. Chan, M.M.-Y. Inhibition of tumor necrosis factor by curcumin, a phytochemical. *Biochem. Pharmacol.* **1995**, *49*, 1551–1556. [CrossRef]

117. Fehl, D.J.; Ahmed, M. Curcumin promotes the oncolytic capacity of vesicular stomatitis virus for the treatment of prostate cancers. *Virus Res.* **2017**, *228*, 14–23. [CrossRef] [PubMed]

118. Adams, J.; Behnke, M.; Chen, S.; Cruickshank, A.A.; Dick, L.R.; Grenier, L.; Klunder, J.M.; Ma, Y.-T.; Plamondon, L.; Stein, R.L. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 333–338. [CrossRef]
119. Palombella, V.J.; Rando, O.J.; Goldberg, A.L.; Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. *Cell* **1994**, *78*, 773–785. [CrossRef]

120. Yarde, D.N.; Nace, R.A.; Russell, S.J. Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo. *Exp. Hematol.* **2013**, *41*, 1038–1049. [CrossRef] [PubMed]

121. Naik, S.; Nace, R.; Federspiel, M.J.; Barber, G.N.; Peng, K.-W.; Russell, S.J. Curative one-shot systemic virotherapy in murine myeloma. *Leukemia* **2012**, *26*, 1870–1878. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).